Indications
Paxlovid is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and paediatric patients 6 years of age and older weighing at least 20 kg who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID 19 (see section 5.1).
Composition
- Active substance
- nirmatrelvir, ritonavir
- International name (INN)
- nirmatrelvir;ritonavir
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Paxlovid
- Active substance
- nirmatrelvir, ritonavir
- ATC code
- J05AE30
- Therapeutic area
- COVID-19 virus infection